早期卵巢透明细胞癌辅助铂类化疗三周期与六周期的比较——多机构队列研究
该回顾性多机构队列纳入1994年1月至2011年12月5家机构治疗的210例IA-II期卵巢透明细胞癌患者,比较接受3周期与6周期辅助铂类(联合或不联合紫杉烷)化疗的生存差异。结果显示两组复发率、无进展生存和总生存均无显著差异,分层及多因素分析亦未见更多化疗获益。
要点
- 210例早期卵巢透明细胞癌中,38例(18.1%)接受3周期、172例(81.9%)接受6周期辅助化疗。
- 3周期与6周期相比,复发率18.4% vs 27.3%(p=0.4),无进展生存HR 1.4(95%CI 0.63-3.12,p=0.4)。
- 总生存HR 1.65(95%CI 0.59-4.65,p=0.3),按分期分层及多因素分析均未见更多化疗获益。
核心结论
- 在早期卵巢透明细胞癌患者中,3周期与6周期铂类联合或不联合紫杉烷辅助化疗在复发和生存方面相当。
研究设计与样本
- 回顾性多机构队列研究,纳入1994年1月至2011年12月5家机构治疗的210例IA-II期卵巢透明细胞癌患者,其中116例接受完整手术分期。
- 患者分为接受3周期与6周期辅助化疗两组,采用Cox比例风险回归和Kaplan-Meier分析评估无进展生存和总生存。
主要发现
- 中位年龄53岁(范围30-88),大多数患者为白人(83.8%),所有患者接受辅助化疗,90%接受卡铂和紫杉醇。
- 38例(18.1%)接受3周期、172例(81.9%)接受6周期辅助化疗。
- 复发率两组相当:3周期组18.4% vs 6周期组27.3%(p=0.4)。
- 单因素分析中,3周期与6周期化疗对无进展生存无影响(HR 1.4;95%CI 0.63-3.12,p=0.4),对总生存无影响(HR 1.65;95%CI 0.59-4.65,p=0.3)。
- 按分期分层分析及调整分期影响的多因素分析均未见更多化疗获益;手术分期患者的亚组分析也显示3周期与6周期化疗生存无差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine if 6 versus 3cycles of adjuvant platinum-based chemotherapy with or without taxane impacts survival in early stage ovarian clear cell carcinoma (OCCC). METHODS: We retrospectively identified all cases of stage I and II OCCC treated at 5 institutions from January 1994 through December 2011. Patients were divided into 2 groups: those who received 3 versus 6cycles of adjuvant chemotherapy. Our cohort consisted of 210 patients with stage IA-II disease, 116 of whom underwent full surgical staging. Cox proportional hazards regression and Kaplan-Meier analyses were performed to evaluate progression-free (PFS) and overall survival (OS) between groups. RESULTS: Among 210 eligible patients, the median age was 53years (range 30-88). The majority of patients were Caucasian (83.8%). All patients received adjuvant chemotherapy with 90% receiving carboplatin and paclitaxel. Thirty-eight (18.1%) patients received 3cycles, and 172 (81.9%) patients received 6cycles of adjuvant treatment. Recurrence rate was comparable between groups (18.4% vs. 27.3% for 3 vs. 6cycles, p=0.4). There was no impact of 3 versus 6cycles of chemotherapy on PFS (hazard ratio [HR] 1.4; 95% confidence interval [CI] 0.63-3.12, p=0.4) or OS (HR 1.65; 95% CI 0.59-4.65, p=0.3) on univariate analysis. There was no benefit to more chemotherapy in stratified analysis by stage nor on multivariate analysis adjusting for the impact of stage. Subgroup analysis of surgically staged patients also showed no difference in survival between 3 versus 6cycles of chemotherapy. CONCLUSIONS: Three cycles of platinum with or without taxane adjuvant chemotherapy were comparable to 6cycles with respect to recurrence and survival in patients diagnosed with early stage ovarian clear cell carcinoma in this retrospective multi-institutional cohort. CONDENSATION: Three cycles of platinum with or without taxane adjuvant chemotherapy are comparable to 6 cycles with respect to recurrence and survival in patients diagnosed with early stage ovarian clear cell carcinoma in this retrospective multi-institutional cohort.
引用
- Prendergast EN, Holzapfel M, Mueller JJ, et al. Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma - A multi-institutional cohort. Gynecol Oncol. 2016. PMID: 27979319. doi:10.1016/j.ygyno.2016.12.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。